Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Patient Capital Management's investment thesis on Precigen ($PGEN) — Q4 2024 | Buyside Digest

$PGENNASDAQPrecigen

BULL

Patient Capital Management—PGEN

Fund Letter

Q4 2024

Published January 13, 2025

$6.93USD

-2.3% vs last month

$1.11Pitched

+524.8% since pitch

Market Cap$2.5B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Precigen is an undervalued cell and gene therapy company poised for its first FDA approval later this year. A recent private...

— Christina Siegel Malbon

BSD Research Exclusive

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

Other investors who've written on Precigen

No other institutional pitches found for this ticker yet.